All In Biotech

Drug Trial Radar · NCT05450692

A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy

A Phase III, Open-label, Randomised, Multicentre Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Without Actionable Genomic Alterations, and Whose Disease Has Progressed On or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy: LATIFY

Last checked: Nov 20, 2026Latest source record: Jul 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 594 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

594

Actual

Start

Sep 15, 2022

Primary completion

Oct 6, 2025

Study completion Dec 31, 2027

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
Parexel
First posted
Jul 11, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 130 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will assess the efficacy and safety of the combination of ceralasertib and durvalumab versus standard of care docetaxel in patients with locally advanced and metastatic NSCLC after progression on prior anti-PD-(L)1 therapy and platinum-based chemotherapy.

Conditions

  • Advanced or Metastatic Non-Small Cell Lung Cancer

Interventions

  • CeralasertibDrug

    Participants will receive ceralasertib oral tablets.

  • DurvalumabDrug

    Participants will receive durvalumab as an intravenous infusion.

  • DocetaxelDrug

    Participants will received docetaxel as an intravenous infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS)Time frame: Every 3 months (± 1 week) following objective progression of disease (PD) or treatment discontinuation (up to three years)

Locations

191 sites in 23 countries. Site status is shown where the registry gives one.

  • Research Site

    Mobile, Alabama

  • Research Site

    Chandler, Arizona

  • Research Site

    Los Alamitos, California

  • Research Site

    Los Angeles, California

  • Research Site

    Whittier, California

  • Research Site

    Jacksonville, Florida

  • Research Site

    Orlando, Florida

  • Research Site

    Athens, Georgia

  • Research Site

    Atlanta, Georgia

  • Research Site

    Fort Wayne, Indiana

  • Research Site

    Baltimore, Maryland

  • Research Site

    Bethesda, Maryland

  • Research Site

    Rockville, Maryland

  • Research Site

    Hattiesburg, Mississippi

  • Research Site

    St Louis, Missouri

  • Research Site

    Omaha, Nebraska

  • Research Site

    Reno, Nevada

  • Research Site

    Charlotte, North Carolina

  • Research Site

    Winston-Salem, North Carolina

  • Research Site

    Canton, Ohio

  • Research Site

    Cleveland, Ohio

  • Research Site

    Allentown, Pennsylvania

  • Research Site

    York, Pennsylvania

  • Research Site

    Houston, Texas

  • Research Site

    Huntsville, Texas

  • Research Site

    Kingwood, Texas

  • Research Site

    Appleton, Wisconsin

  • Research Site

    Buenos Aires, Argentina

  • Research Site

    Pergamino, Argentina

  • Research Site

    Rosario, Argentina

  • Research Site

    Rosario, Argentina

  • Research Site

    San Juan, Argentina

  • Research Site

    Elizabeth Vale, Australia

  • Research Site

    Lismore, Australia

  • Research Site

    Murdoch, Australia

  • Research Site

    South Brisbane, Australia

  • Research Site

    Wollongong, Australia

  • Research Site

    Charleroi, Belgium

  • Research Site

    Ghent, Belgium

  • Research Site

    Libramont-Chevigny, Belgium

Showing 40 of 191 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.